RÉSUMÉ
BACKGROUND: The predictive value of systemic inflammatory response index (SIRI) for stroke-associated pneumonia (SAP) risk in patients with acute ischemic stroke (AIS) treated by thrombectomy remains unclear. This study aimed to investigate the predictive value of SIRI for SAP in patients with AIS treated by thrombectomy. METHODS: We included AIS patients treated by thrombectomy between August 2018 and August 2022 at our institute. We used multivariate logistic regression to construct the prediction model and performed a receiver operating characteristic curve analysis to evaluate the ability of SIRI to predict SAP and constructed a calibration curve to evaluate the prediction accuracy of the model. We evaluated the clinical application value of the nomogram using decision curve analysis. RESULTS: We included 84 eligible patients with AIS in the analysis, among which 56 (66.7%) had SAP. In the univariate analysis, there were significant differences in sex (p = 0.035), National Institute of Health Stroke Scale score at admission ≥ 20 (p = 0.019) and SIRI (p < 0.001). The results of multivariable logistic analysis showed that the risk of SAP increased with the SIRI value (OR = 1.169, 95% CI = 1.049-1.344, p = 0.014). Age ≥ 60 (OR = 4.076, 95% CI = 1.251-14.841, p = 0.024) was also statistically significant. A nomogram with SIRI showed good prediction accuracy for SAP in AIS patients treated by thrombectomy (C-index value = 0.774). CONCLUSIONS: SIRI is an independent predictor for SAP in patients with AIS treated by thrombectomy. A high SIRI value may allow for the early identification of patients with AIS treated by thrombectomy at high risk for SAP.
Sujet(s)
Accident vasculaire cérébral ischémique , Pneumopathie infectieuse , Thrombectomie , Humains , Mâle , Femelle , Accident vasculaire cérébral ischémique/chirurgie , Accident vasculaire cérébral ischémique/complications , Accident vasculaire cérébral ischémique/diagnostic , Sujet âgé , Études rétrospectives , Thrombectomie/méthodes , Adulte d'âge moyen , Pneumopathie infectieuse/diagnostic , Pneumopathie infectieuse/épidémiologie , Valeur prédictive des tests , Nomogrammes , Sujet âgé de 80 ans ou plus , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologieRÉSUMÉ
BACKGROUND: Baseline anemia is associated with poor intracerebral hemorrhage (ICH) outcomes. However, underlying drivers for anemia and whether anemia development after ICH impacts clinical outcomes are unknown. We hypothesized that inflammation drives anemia development after ICH and assessed their relationship to outcomes. METHODS AND RESULTS: Patients with serial hemoglobin and iron biomarker concentrations from the HIDEF (High-Dose Deferoxamine in Intracerebral Hemorrhage) trial were analyzed. Adjusted linear mixed models assessed laboratory changes over time. Of 42 patients, significant decrements in hemoglobin occurred with anemia increasing from 19% to 45% by day 5. Anemia of inflammation iron biomarker criteria was met in 88%. A separate cohort of 521 patients with ICH with more granular serial hemoglobin and long-term neurological outcome data was also investigated. Separate regression models assessed whether (1) systemic inflammatory response syndrome (SIRS) scores related to hemoglobin changes over time and (2) hemoglobin changes related to poor 90-day outcome. In this cohort, anemia prevalence increased from 30% to 71% within 2 days of admission yet persisted beyond this time. Elevated systemic inflammatory response syndrome was associated with greater hemoglobin decrements over time (adjusted parameter estimate: -0.27 [95% CI, -0.37 to -0.17]) and greater hemoglobin decrements were associated with poor outcomes (adjusted odds ratio per 1 g/dL increase, 0.76 [95% CI, 0.62-0.93]) independent to inflammation and ICH severity. CONCLUSIONS: We identified novel findings that acute anemia development after ICH is common, rapid, and related to inflammation. Because anemia development is associated with poor outcomes, further work is required to clarify if anemia, or its underlying drivers, are modifiable treatment targets that can improve ICH outcomes. REGISTRATION: https://www.clinicaltrials.gov Unique identifier: NCT01662895.
Sujet(s)
Anémie , Marqueurs biologiques , Hémorragie cérébrale , Hémoglobines , Inflammation , Humains , Hémorragie cérébrale/sang , Hémorragie cérébrale/diagnostic , Hémorragie cérébrale/épidémiologie , Mâle , Femelle , Anémie/sang , Anémie/diagnostic , Anémie/épidémiologie , Sujet âgé , Adulte d'âge moyen , Marqueurs biologiques/sang , Hémoglobines/métabolisme , Hémoglobines/analyse , Inflammation/sang , Syndrome de réponse inflammatoire généralisée/sang , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologie , Déferoxamine/usage thérapeutique , Facteurs temps , Résultat thérapeutique , Fer/sang , PrévalenceRÉSUMÉ
The COVID-19 pandemic reshaped the landscape of respiratory viral illnesses, causing common viruses to fade as SARS-CoV-2 took precedence. By 2023, more than 96% of the children in the United States were estimated to have been infected with SARS-CoV-2, with certain genetic predispositions and underlying health conditions posing risk factors for severe disease in children. Children, in general though, exhibit immunity advantages, protecting against aspects of the SARS-CoV-2 infection known to drive increased severity in older adults. Post-COVID-19 complications such as multisystem inflammatory syndrome in children and long COVID have emerged, underscoring the importance of vaccination. Here, we highlight the risks of severe pediatric COVID-19, age-specific immunoprotection, comparisons of SARS-CoV-2 with other respiratory viruses, and factors contributing to post-COVID-19 complications in children.
Sujet(s)
COVID-19 , SARS-CoV-2 , Humains , COVID-19/épidémiologie , COVID-19/complications , Enfant , Syndrome de réponse inflammatoire généralisée/épidémiologie , Syndrome de réponse inflammatoire généralisée/thérapie , Enfant d'âge préscolaire , Facteurs de risque , Facteurs âgesRÉSUMÉ
Multisystemic inflammatory syndrome in children (MIS-C) might manifest in a broad spectrum of clinical scenarios, ranging from mild features to multi-organ dysfunction and mortality. However, this novel entity has a heterogenicity of data regarding prognostic factors associated with severe outcomes. The present study aimed to identify independent predictors for severity by using multivariate regression models. A total of 391 patients (255 boys and 136 girls) were admitted to Vietnam National Children's Hospital from January 2022 to June 2023. The median age was 85 (range: 2-188) months, and only 12 (3.1%) patients had comorbidities. 161 (41.2%) patients required PICU admission, and the median PICU LOS was 4 (2-7) days. We observed independent factors related to PICU admission, including CRP ≥ 50 (mg/L) (OR 2.52, 95% CI 1.39-4.56, p = 0.002), albumin ≤ 30 (g/L) (OR 3.18, 95% CI 1.63-6.02, p = 0.001), absolute lymphocyte count ≤ 2 (× 109/L) (OR 2.18, 95% CI 1.29-3.71, p = 0.004), ferritin ≥ 300 (ng/mL) (OR 2.35, 95% CI 1.38-4.01), p = 0.002), and LVEF < 60 (%) (OR 2.48, 95% CI 1.28-4.78, p = 0.007). Shock developed in 140 (35.8%) patients, especially for those decreased absolute lymphocyte ≤ 2 (× 109/L) (OR 2.48, 95% CI 1.10-5.61, p = 0.029), albumin ≤ 30 (g/L) (OR 2.53, 95% CI 1.22-5.24, p = 0.013), or LVEF < 60 (%) (OR 2.24, 95% CI 1.12-4.51, p = 0.022). In conclusion, our study emphasized that absolute lymphocyte count, serum albumin, CRP, and LVEF were independent predictors for MIS-C severity. Further well-designed investigations are required to validate their efficacy in predicting MIS-C severe cases, especially compared to other parameters. As MIS-C is a new entity and severe courses may progress aggressively, identifying high-risk patients optimizes clinicians' follow-up and management to improve disease outcomes.
Sujet(s)
COVID-19 , Indice de gravité de la maladie , Syndrome de réponse inflammatoire généralisée , Humains , Mâle , Femelle , Enfant , COVID-19/épidémiologie , COVID-19/diagnostic , COVID-19/complications , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologie , Vietnam/épidémiologie , Enfant d'âge préscolaire , Adolescent , Nourrisson , SARS-CoV-2/isolement et purification , Pronostic , Numération des lymphocytes , Unités de soins intensifs pédiatriques , Protéine C-réactive/analyse , Protéine C-réactive/métabolismeRÉSUMÉ
Importance: Neurological manifestations during acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity. Objective: To assess the association of severe neurological manifestations during a SARS-CoV-2-related hospital admission with new neurocognitive or functional morbidities at discharge. Design, Setting, and Participants: This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021. Exposure: Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke. Main Outcomes and Measures: The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2-related condition. Results: Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P < .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations (P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge. Conclusions and Relevance: The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
Sujet(s)
COVID-19 , Hospitalisation , Maladies du système nerveux , SARS-CoV-2 , Syndrome de réponse inflammatoire généralisée , Humains , COVID-19/complications , COVID-19/épidémiologie , Enfant , Femelle , Mâle , Enfant d'âge préscolaire , Hospitalisation/statistiques et données numériques , Adolescent , Études prospectives , Syndrome de réponse inflammatoire généralisée/épidémiologie , Maladies du système nerveux/étiologie , Maladies du système nerveux/épidémiologie , Nourrisson , Indice de gravité de la maladieRÉSUMÉ
OBJECTIVES: The aim of the study was to establish an international multicenter registry to collect data on patients with Multisystem Inflammatory Syndrome in Children (MIS-C), in order to highlight a relationship between clinical presentation, age of onset and geographical distribution on the clinical outcome. STUDY DESIGN: Multicenter retrospective study involving different international societies for rare immunological disorders.1009 patients diagnosed with MIS-C between March and September 2022, from 48 centers and 22 countries were collected. Five age groups (<1, 1-4, 5-11, 12-16, >16 years) and four geographic macro-areas, Western Europe, Central-Eastern Europe, Latin America, Asian-African resource-limited countries (LRC), were identified. RESULTS: Time to referral was significantly higher in LRC. Intensive anti-inflammatory treatment, including biologics, respiratory support and mechanic ventilation were more frequently used in older children and in European countries. The mortality rate was higher in very young children (<1 year), in older patients (>16 years of age) and in LRC. Multivariate analysis identified the residence in LRC, presence of severe cardiac involvement, renal hypertension, lymphopenia and non-use of heparin prophylaxis, as the factors most strongly associated with unfavorable outcomes. CONCLUSIONS: The stratification of patients by age and geographic macro-area provided insights into the clinical presentation, treatment and outcome of MIS-C. The mortality and sequelae rates exhibited a correlation with the age and geographical areas. Patients admitted and treated in LRC displayed more severe outcomes, possibly due to delays in hospital admission and limited access to biologic drugs and to intensive care facilities.
Sujet(s)
Âge de début , COVID-19 , Enregistrements , SARS-CoV-2 , Syndrome de réponse inflammatoire généralisée , Humains , Enfant , COVID-19/épidémiologie , COVID-19/mortalité , COVID-19/complications , Enfant d'âge préscolaire , Femelle , Mâle , Nourrisson , Adolescent , Études rétrospectives , Syndrome de réponse inflammatoire généralisée/épidémiologie , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/thérapie , Europe/épidémiologie , Nouveau-néRÉSUMÉ
OBJECTIVE: Neonatal multisystem inflammatory syndrome (MIS-N) is a unique disease of neonates described in several case reports from all over the world with a myriad of presentations and the emergence of new cases. STUDY DESIGN: Retrospective case series. Place and Duration of the Study: Department of Paediatrics, Fazaia Medical College, Pakistan Air Force Hospital, Islamabad, Pakistan, from December 2021 to November 2022. METHODOLOGY: The study was conducted on neonates who were managed as MIS-N in the neonatal ICU. Data were collected and analysed on SPSS version 24. RESULTS: Patients in this study ranged from newborns to 13 days of age with a mean age of 3.27 ± 4.29 days and average gestational age of 35.18 ± 3.67 weeks. Among these neonates, 7 (63.6%) had bleeding diathesis, 11 (100%) had seizures, 8 (72.2%) presented with haemodynamic instability and shock, and 7 (63.3%) had signs of heart failure. All neonates (100%) had markedly raised SARS-CoV2 IgG antibodies, CRP, ferritin, D-dimers, interleukin 6, procalcitonin, 10 (90.9%) had hypoalbuminemia, and 7 (63.3%) had deranged coagulation profile. Cardiac involvement was seen in all neonates (100%) with raised proBNP and myocardial dysfunction on echocardiography. Pulmonary hypertension was present in 6 (54.4%) neonates. High mortality was observed at 6 (54.5%) among which 4 (66.6%) were premature neonates. CONCLUSION: MIS-N is a new disease entity which is still under research. There is a high propensity for cardiovascular system involvement and higher mortality among preterm neonates. KEY WORDS: Neonatal multisystem inflammatory syndrome (MIS-N), Multisystem inflammatory syndrome in children (MIS-C), SARS-CoV2 infection, SARS-CoV2 spike protein, SARS-CoV2 IgG antibodies.
Sujet(s)
COVID-19 , Unités de soins intensifs néonatals , SARS-CoV-2 , Syndrome de réponse inflammatoire généralisée , Centres de soins tertiaires , Humains , COVID-19/complications , COVID-19/épidémiologie , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologie , Nouveau-né , Femelle , Mâle , Études rétrospectives , Pakistan/épidémiologieRÉSUMÉ
Objective: The objective is to expose the cardiovascular alterations in patients diagnosed with pediatric inflammatory multisystem syndrome (PIMS) associated with COVID-19 during the SARS-CoV-2 pandemic, in order to understand the disease, its evolution, and optimal management upon diagnosis. Method: Retrospective, observational, cross-sectional analytical study of patients diagnosed with PIMS according to the criteria of the World Health Organization at the National Institute of Pediatrics, from March 2020 to December 2021. Results: During the study period, 77 patients with PIMS were diagnosed. The results showed correlation between the shock state and alteration of laboratory markers (platelets 144217.29 ± 139321.6 µL [p < 0.001], procalcitonin 27.37 ± 38.37 ng/ml [p = 0.05] and ferritin 1937.87 ± 2562.63 [p < 0.001]). The ventricular function in patients with shock was significantly lower compared to those without shock (49.6 ± 9.1% vs. 58.1 ± 8.4 %; t-Student p < 0.001), as well as injury to the left coronary artery (p = 0.02). There is a correlation between NT-proBNP and ventricular dysfunction (Kruskal-Wallis p = 0.007). Statistical significance was found in the association between death, elevation of inflammatory markers and ventricular dysfunction (p < 0.001). Conclusions: The cardiovascular alterations observed, in order of frequency, were pericardial effusion (25.7%), myocarditis (15%), mild ventricular dysfunction (13.5%) and small coronary aneurysm with predominance of the left coronary artery and the anterior descending one.
Objetivo: Exponer las alteraciones cardiovasculares en los pacientes diagnosticados con síndrome inflamatorio multisistémico pediátrico (PIMS) asociado a COVID-19 durante la pandemia por SARS-CoV-2 con el fin de comprender la enfermedad, su evolución y el manejo óptimo al diagnóstico. Método: Estudio retrospectivo, observacional, transversal y analítico de pacientes con diagnóstico de PIMS de acuerdo con los criterios de la Organización Mundial de la Salud en el Instituto Nacional de Pediatría, de marzo de 2020 a diciembre de 2021. Resultados: Durante el periodo de estudio se diagnosticaron 77 pacientes con PIMS. Los resultados demostraron una correlación entre el estado de choque y la alteración de los marcadores de laboratorio (plaquetas 144217.29 ± 139321.6 µl [p < 0.001], procalcitonina 27.37 ± 38.37 ng/ml [p = 0.05] y ferritina 1937.87 ± 2562.63 [p < 0.001]). La función ventricular en los pacientes con choque se registró significativamente menor en comparación con aquellos sin choque (49.6 ± 9.1 % vs. 58.1 ± 8.4 %; t de Student p < 0.001), así como lesión en la arteria coronaria izquierda (p = 0.02). Existe una correlación entre el NT-proBNP y la disfunción ventricular (Kruskal-Wallis p = 0.007). Se encontró significancia estadística en la asociación entre fallecimiento, elevación de los marcadores inflamatorios y disfunción ventricular (p < 0.001). Conclusiones: Las alteraciones cardiovasculares observadas fueron, en orden de frecuencia, derrame pericárdico (25.7%), miocarditis (15%), disfunción ventricular leve (13.5%) y aneurisma pequeño coronario con predominio de la arteria coronaria izquierda y la descendente anterior.
Sujet(s)
COVID-19 , Syndrome de réponse inflammatoire généralisée , Humains , COVID-19/complications , Mexique/épidémiologie , Syndrome de réponse inflammatoire généralisée/étiologie , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologie , Études transversales , Mâle , Femelle , Études rétrospectives , Enfant , Enfant d'âge préscolaire , Adolescent , Centres de soins tertiaires , Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/épidémiologie , Nourrisson , Choc/étiologieRÉSUMÉ
OBJECTIVES: This study sought to investigate the relationship between the systemic inflammatory response index (SIRI) and bone mineral density (BMD), osteoporosis, and future fracture risk in elderly hypertensive patients. METHODS: Elderly hypertensive patients (age ≥60 years) who attended our hospital between January 2021 and December 2023 and completed BMD screening were included in the study. Analyses were performed with multivariate logistic and linear regression. RESULTS: The multiple linear regression indicated that SIRI levels were significantly negatively correlated with lumbar 1 BMD (ß = -0.15, 95% CI: -0.24, -0.05), lumbar 2 BMD (ß = -0.15, 95% CI: -0.24, -0.05), lumbar 3 BMD (ß = -1.35, 95% CI: -0.23, -0.02), lumbar 4 BMD (ß = -0.11, 95% CI: -0.30, -0.10), femur neck BMD (ß = -0.11, 95% CI: -0.18, -0.05) and Ward's triangle BMD (ß = -0.12, 95% CI: -0.20, -0.05) among elderly hypertensive patients, after fully adjusting for confounders. Furthermore, we observed that SIRI was positively associated with future fracture risk in elderly hypertensive patients. Specifically, SIRI was associated with an increased risk of major osteoporotic fractures (ß = 0.33) and hip fractures (ß = 0.25). The logistic regression analysis indicated that there is an association between the SIRI level and an increased risk of osteoporosis (OR = 1.60, 95% CI = 1.37, 1.87), after fully adjusting for confounders. CONCLUSIONS: Our findings indicate a potential association between SIRI and BMD, osteoporosis, and the risk of future fractures in elderly hypertensive patients. However, further studies are warranted to confirm these findings.
Sujet(s)
Densité osseuse , Hypertension artérielle , Ostéoporose , Humains , Femelle , Mâle , Sujet âgé , Ostéoporose/épidémiologie , Hypertension artérielle/épidémiologie , Hypertension artérielle/complications , Adulte d'âge moyen , Facteurs de risque , Fractures ostéoporotiques/épidémiologie , Fractures ostéoporotiques/étiologie , Appréciation des risques/méthodes , Sujet âgé de 80 ans ou plus , Syndrome de réponse inflammatoire généralisée/épidémiologie , Vertèbres lombales/imagerie diagnostique , Absorptiométrie photoniqueRÉSUMÉ
Multisystemic inflammatory syndrome in children (MIS-C) is a rare, severe, post-infectious hyperinflammatory condition that occurs after COVID-19 infection. In this study, we aimed to demonstrate the risk reduction of MIS-C and severe MIS-C after Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccination. This nationwide cohort study included 526,685 PCR-confirmed COVID-19 cases (age < 19 years), of whom 14,118 were fully vaccinated prior to COVID-19 infection. MIS-C cases were collected from all hospitals in Israel from April 2020 through November 2021. The MIS-C rates were calculated among two COVID-19 populations: positive PCR confirmed cases and estimated COVID-19 cases (PCR confirmed and presumed). Vaccination status was determined from Ministry of Health (MoH) records. The MIS-C risk difference (RD) and 95% confidence intervals (95%CI) between vaccinated and unvaccinated patients are presented. Overall, 233 MIS-C cases under the age of 19 years were diagnosed and hospitalized in Israel during the study period. Among the estimated COVID-19 cases, MIS-C RD realistically ranged between 2.1 [95%CI 0.7-3.4] and 1.0 [95%CI 0.4-1.7] per 10,000 COVID-19 cases. For severe MIS-C, RD realistically ranged between 1.6 [95%CI 1.3-1.9] and 0.8 [95%CI 0.7-1.0], per 10,000 COVID-19 cases. Sensitivity analysis was performed on a wide range of presumed COVID-19 rates, demonstrating significant RD for each of these rates. CONCLUSION: This research demonstrates that vaccinating children and adolescents against COVID-19 has reduced the risk of MIS-C during the study period. WHAT IS KNOWN: ⢠Most of the published literature regarding vaccine effectiveness is based on case-control studies, which are limited due to small sample sizes and the inability to fully estimate the risk of MIS-C among vaccinated and unvaccinated children and adolescents. ⢠The known underestimation of COVID-19 diagnosis among children and adolescents is challenging, as they often have few to no symptoms. WHAT IS NEW: ⢠Significant risk difference was found in favor of the vaccinated group, even after including extreme assumptions regarding the underdiagnosed COVID-19 rate. ⢠During this nationwide study period, it was found that vaccinating children and adolescents reduced the risk of MIS-C and its complications.
Sujet(s)
Vaccin BNT162 , COVID-19 , Syndrome de réponse inflammatoire généralisée , Humains , COVID-19/prévention et contrôle , COVID-19/épidémiologie , COVID-19/complications , Enfant , Israël/épidémiologie , Adolescent , Mâle , Femelle , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/prévention et contrôle , Syndrome de réponse inflammatoire généralisée/épidémiologie , Enfant d'âge préscolaire , Nourrisson , Études de cohortes , Vaccination/statistiques et données numériques , Vaccins contre la COVID-19/effets indésirables , SARS-CoV-2/immunologieRÉSUMÉ
The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1-42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0-5) and 5 (95%CI 3-6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0-23) hospitalisations with epilepsy and 4 (95%CI 0-6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.
Sujet(s)
Vaccin BNT162 , Vaccins contre la COVID-19 , COVID-19 , Vaccin ChAdOx1 nCoV-19 , Hospitalisation , SARS-CoV-2 , Vaccination , Humains , COVID-19/prévention et contrôle , COVID-19/épidémiologie , COVID-19/complications , Enfant , Femelle , Angleterre/épidémiologie , Mâle , Enfant d'âge préscolaire , Adolescent , SARS-CoV-2/immunologie , Vaccins contre la COVID-19/effets indésirables , Vaccins contre la COVID-19/administration et posologie , Hospitalisation/statistiques et données numériques , Vaccination/effets indésirables , Myocardite/épidémiologie , Vaccin ARNm-1273 contre la COVID-19 , Syndrome de réponse inflammatoire généralisée/épidémiologie , Névrite optique/épidémiologie , Épilepsie/épidémiologieRÉSUMÉ
INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is the main cause of death in burns and is associated with high burn mortality rates. SIRS occurs when burns are in the subacute phase and is affected by several factors, such as host, trauma and management. The research was conducted at the Burn Center of Dr Soetomo General Hospital, Surabaya, Indonesia, using retrospective observational analytic research design. The aim of the study was to assess the correlation of risk factors which include age, extent of burns, cause of burns, inhalation trauma, history of hyperglycaemia, anaemia, hypoalbuminemia and ESBL infection with the incidence of SIRS. MATERIALS AND METHODS: The study is observational analytic research using a retrospective design and secondary data of all burn patients treated at the Burn Center of Dr Soetomo General Hospital, Surabaya, Indonesia from January 2018 to December 2019. RESULTS: A total of 163 burn patients were included. Among comorbidities found were inhalation trauma (39.3%), diabetes mellitus (2.5%), anaemia (14.7%), hypoalbuminemia (40.5%) and ESBL infection (1.2%). A total of 11 patients (6.7%) suffered from SIRS. The statistical analysis showed that anaemia (p=0.012), hypoalbuminemia (p=0.030) and the percentage of burns (p=0.001) were significantly correlated to the incidence of SIRS while age, sex, cause of burn injury, inhalation trauma, diabetes mellitus and ESBL infection have no significant correlation with SIRS. CONCLUSION: Burn surface area is the most influencing factor of SIRS incident. It is important to meticulously monitor patients with extensive burn areas for indications of SIRS. However, the sample size of this study was relatively small, and it used a retrospective approach, so a larger sample size and a prospective or cohort design method were recommended for further study.
Sujet(s)
Brûlures , Syndrome de réponse inflammatoire généralisée , Humains , Indonésie/épidémiologie , Mâle , Femelle , Études rétrospectives , Adulte , Syndrome de réponse inflammatoire généralisée/épidémiologie , Brûlures/complications , Brûlures/épidémiologie , Facteurs de risque , Adulte d'âge moyen , Unités de soins intensifs de brûlés , Jeune adulte , Adolescent , Hôpitaux généraux , Sujet âgé , IncidenceRÉSUMÉ
OBJECTIVE: In this study, we aimed to evaluate the death risk factors of patients included in the sepsis protocol bundle, using clinical data from qSOFA, SIRS, and comorbidities, as well as development of a mortality risk score. DESIGN: This retrospective cohort study was conducted between 2016 and 2021. SETTING: Two university hospitals in Brazil. PARTICIPANTS: Patients with sepsis. INTERVENTIONS: Several clinical and laboratory data were collected focused on SIRS, qSOFA, and comorbidities. MAIN VARIABLE OF INTEREST: In-hospital mortality was the primary outcome variable. A mortality risk score was developed after logistic regression analysis. RESULTS: A total of 1,808 patients were included with a death rate of 36%. Ten variables remained independent factors related to death in multivariate analysis: temperature ≥38⯰C (odds ratio [OR]â¯=â¯0.65), previous sepsis (ORâ¯=â¯1.42), qSOFAâ¯≥â¯2 (ORâ¯=â¯1.43), leukocytes >12,000 or <4,000â¯cells/mm3 (ORâ¯=â¯1.61), encephalic vascular accident (ORâ¯=â¯1.88), age >60 years (ORâ¯=â¯1.93), cancer (ORâ¯=â¯2.2), length of hospital stay before sepsis >7 days (ORâ¯=â¯2.22,), dialysis (ORâ¯=â¯2.51), and cirrhosis (ORâ¯=â¯3.97). Considering the equation of the binary regression logistic analysis, the score presented an area under curve of 0.668, is not a potential model for death prediction. CONCLUSIONS: Several risk factors are independently associated with mortality, allowing the development of a prediction score based on qSOFA, SIRS, and comorbidities data, however, the performance of this score is low.
Sujet(s)
Comorbidité , Mortalité hospitalière , Scores de dysfonction d'organes , Sepsie , Syndrome de réponse inflammatoire généralisée , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Brésil/épidémiologie , Études rétrospectives , Appréciation des risques/méthodes , Facteurs de risque , Sepsie/mortalité , Syndrome de réponse inflammatoire généralisée/mortalité , Syndrome de réponse inflammatoire généralisée/épidémiologieRÉSUMÉ
OBJECTIVES: To compare Kawasaki disease (KD) and multisystem inflammatory syndrome (MIS-C) in children. METHODS: Prospective collection of demographics, clinical and treatment data. Assessment of type 1 interferon (IFN) score, CXCL9, CXCL10, Interleukin (IL)18, IFNγ, IL6, IL1b at disease onset and at recovery. RESULTS: 87 patients (43 KD, 44 MIS-C) were included. Age was higher in MIS-C compared to KD group (mean 31±23 vs. 94±50 months, p<0.001). Extremities abnormalities (p=0.027), mucosal involvement (p<0.001), irritability (p<0.001), gallbladder hydrops (p=0.01) and lymphadenopathy (p=0.07) were more often recorded in KD. Neurological findings (p=0.002), gastrointestinal symptoms (p=0.013), respiratory involvement (p=0.019) and splenomegaly (p=0.026) were more frequently observed in MIS-C. Cardiac manifestations were higher in MIS-C (p<0.001), although coronary aneurisms were more frequent in KD (p=0.012). In the MIS-C group, the multiple linear regression analysis revealed that a higher IFN score at onset was related to myocardial disfunction (p<0.001), lymphadenopathy (p=<0.001) and need of ventilation (p=0.024). Both CXCL9 and CXCL10 were related to myocardial disfunction (p<0.001 and p=0.029). IL18 was positively associated to PICU admission (0.030) and ventilation (p=004) and negatively associated to lymphadenopathy (0.004). IFNγ values were related to neurological involvement and lymphadenopathy (p<0.001), IL1b to hearth involvement (0.006). A negative correlation has been observed between IL6 values, heart involvement (p=0.013) and PICU admission (p<0.001). CONCLUSIONS: The demographic and clinical differences between KD e MIS-C cohorts confirm previous reported data. The assessment of biomarkers levels at MIS-C onset could be useful to predict a more severe disease course and the development of cardiac complications.
Sujet(s)
COVID-19/complications , Maladie de Kawasaki , Syndrome de réponse inflammatoire généralisée , Humains , Maladie de Kawasaki/diagnostic , Maladie de Kawasaki/complications , Maladie de Kawasaki/épidémiologie , Maladie de Kawasaki/physiopathologie , Mâle , Femelle , Enfant d'âge préscolaire , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologie , Enfant , Études prospectives , Nourrisson , COVID-19/diagnostic , Marqueurs biologiques/sangRÉSUMÉ
INTRODUCTION AND OBJECTIVE: Several studies have suggested that the hospitalization rate for COVID-19 in children and adolescents may reflect the prevalence of the infection rather than the severity of the disease. The aim of this study was to describe the clinical features of hospitalised paediatric patients with SARS-CoV-2 infection in order to understand if the infection was the reason for admission. METHODS: Retrospective cohort study including patients aged 0-18 years with SARS-CoV-2 infection or multisystem inflammatory syndrome in children (MIS-C) admitted to a tertiary care children's hospital in Spain between 01/01/2020 and 12/31/2021. RESULTS: 228 patients were included, corresponding to 150 cases of COVID-related admission (SARS-CoV-2 infection as main cause of hospitalization) and 78 of non-COVID-related admission (SARS-CoV-2 infection unrelated to the hospitalization). In the group of COVID-related admissions, 58 patients had comorbidities. Forty-nine patients had acute respiratory disease (pneumonia, bronchospasm or bronchiolitis). Multisystem inflammatory syndrome in children was diagnosed in 27 and was significantly more frequent in the first year of the pandemic (wild type virus). Eighty percent of patients with acute respiratory disease needed respiratory support, mostly low-flow oxygen therapy. The severity of the disease was similar in all virus variants. Two patients (both with severe comorbidities) died from COVID-related conditions. CONCLUSIONS: In our study, one third of the patients were admitted with SARS-CoV-2 infection but not because of it. Acute respiratory disease was less frequent and had a better prognosis compared to the adult population, while MIS-C was a major cause of morbidity and hospitalization. The fatality rate was extremely low.
Sujet(s)
COVID-19 , Hospitalisation , Syndrome de réponse inflammatoire généralisée , Humains , COVID-19/épidémiologie , COVID-19/thérapie , COVID-19/mortalité , COVID-19/complications , Études rétrospectives , Enfant , Nourrisson , Enfant d'âge préscolaire , Mâle , Femelle , Adolescent , Espagne/épidémiologie , Hospitalisation/statistiques et données numériques , Syndrome de réponse inflammatoire généralisée/épidémiologie , Syndrome de réponse inflammatoire généralisée/thérapie , Syndrome de réponse inflammatoire généralisée/diagnostic , Nouveau-né , Études de cohortes , Indice de gravité de la maladieRÉSUMÉ
PURPOSE: In light of the growing concern over the possible link between SARS-CoV2 infection and autoimmune diseases, we conducted a review to investigate the impact of the pandemic outbreak on thyroid diseases. METHODS: We carried out a narrative review of all pediatric cases described in the literature, mainly focusing on the possible association of COVID-19 with the incidence of autoimmune and post-infective thyroid diseases (namely Hashimoto's Thyroiditis (HT), Grave's Disease (GD) and Sub-Acute Thyroiditis (SAT)). We also felt it was necessary to provide a brief review of Non-thyroidal Illness Syndrome (NTIS) and Multisystem Inflammatory Syndrome in Children (MIS-C) because of their overlap with thyroiditis. RESULTS: There is currently no conclusive evidence linking SARS-CoV-2 infection with an increased incidence of autoimmune thyroiditis (AT) in pediatric age. However, SAT may be a mild complication of SARS-CoV-2 infection, as is the case with other viral infections. SAT typically resolves on its own and does not require treatment. NTIS may be associated with inflammatory complications, such as MIS-C, and admission to intensive care. It may also be considered a prognostic risk factor for severe disease. The hypothesized pathogenetic mechanisms of thyroid damage in COVID-19 include direct damage due to the significant expression of angiotensin-converting enzyme 2 (ACE2) in the thyroid gland, which is a ligand for the virus, and indirect damage due to immune dysregulation, such as the overproduction of IL-6, which is thought to be part of the pathogenesis of thyroiditis. CONCLUSION: However, due to the limited evidence available, further prospective longitudinal studies are required to clarify the relationship between COVID-19 and thyroid disease in children and adolescents, as well as to investigate any potential long-term consequences.
Sujet(s)
COVID-19 , Humains , COVID-19/complications , COVID-19/épidémiologie , Enfant , SARS-CoV-2 , Maladie de Hashimoto/épidémiologie , Adolescent , Syndrome de réponse inflammatoire généralisée/épidémiologie , Thyroïdite/épidémiologie , Incidence , Maladie de Basedow/épidémiologie , Maladie de Basedow/complicationsRÉSUMÉ
BACKGROUND: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 infection, characterized by a range of clinical symptoms with varying severity. Understanding risk factors for severe PIMS-TS is crucial for appropriate and timely intervention. OBJECTIVE: To identify factors associated with increased PIMS-TS severity in children. METHODS: In this nationwide prospective observational study, epidemiological and clinical data was collected from children <18 years of age with suspected or confirmed PIMS-TS from all 29 pediatric hospitals in Switzerland. Children were categorized into 3 groups according to admission to intensive care unit (ICU): non-ICU, ICU-moderate and ICU-severe, defined as requirement of invasive ventilation and/or inotropic support. RESULTS: A total of 204 children were included; 99 (49%) were categorized as non-ICU, 50 (25%) as ICU-moderate and 55 (27%) as ICU-severe. In ICU-severe cases, respiratory and neurological symptoms were more frequent compared with non-ICU cases: 72% versus 47%, P < 0.001 and 66% versus 41%, P = 0.001, respectively. Compared with the non-ICU group, children in the ICU-severe group had lower lymphocyte counts, higher neutrophil-lymphocyte ratios, lower platelet counts, as well as higher C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin T and creatinine levels at admission. Lymphopenia and elevated troponin T levels at admission were associated with an increased risk of being in the ICU-severe group. CONCLUSION: The severity of PIMS-TS may be predicted using clinical symptoms and laboratory biomarkers, which help clinicians in decision-making and management of patients.
Sujet(s)
Marqueurs biologiques , COVID-19 , SARS-CoV-2 , Indice de gravité de la maladie , Syndrome de réponse inflammatoire généralisée , Humains , COVID-19/sang , COVID-19/épidémiologie , COVID-19/diagnostic , COVID-19/complications , Suisse/épidémiologie , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/sang , Syndrome de réponse inflammatoire généralisée/épidémiologie , Enfant , Études prospectives , Mâle , Femelle , Enfant d'âge préscolaire , Marqueurs biologiques/sang , Nourrisson , Adolescent , Facteurs de risqueRÉSUMÉ
INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is one of the most serious complications in patients undergoing percutaneous nephrolithotomy (PCNL). Although glucocorticoids are increasingly used during PCNL, few studies have been concerned about the association between glucocorticoids and postoperative SIRS. The study aims to explore whether preoperative use of glucocorticoids is associated with SIRS after PCNL. METHODS: A total of 1259 patients who underwent PCNL between January 2015 and April 2021 were enrolled in the retrospective cohort study. Risk factors for post-PCNL SIRS were identified by univariate and multivariate regression analysis. To further explore the association between preoperative administration of glucocorticoids and SIRS, 113 pairs of patients were matched for the confounding factors using propensity score matching (PSM) analysis. The odds ratios (OR) and 95 % confidence intervals (CI) for the above variables were analyzed. RESULTS: The incidence of SIRS after PCNL was 9.6 % (121/1259) and the patients who suffered from postoperative SIRS had longer hospital stays and higher hospital costs (all p < 0.05). Multivariate logistic regression analysis indicated that female, preoperative leukocyte count, insertion of central vein catheter, serum albumin, preoperative high-sensitive C-reactive protein/albumin ratio, preoperative transfusion, preoperative administration of glucocorticoids were independent risk factors for SIRS (all p < 0.05). After minimization, the effects of confounding factors by PSM, preoperative administration of glucocorticoids was significantly correlated with SIRS in patients after PCNL (OR=2.44, 95 %CI: 1.31-4.55, p = 0.005). CONCLUSION: Preoperative administration of glucocorticoids is an independent risk factor for SIRS in patients undergoing PCNL.
Systemic inflammatory response syndrome (SIRS) is a frequent and severe complication in patients underwent percutaneous nephrolithotomy (PCNL), which can be challenging to diagnose early, potentially leading to delayed treatment. Identifying SIRS risk factors and promptly treating high-risk patients is crucial. Glucocorticoids are commonly used to prevent SIRS in clinical practice, and this study aims to investigate whether preoperative glucocorticoid administration is associated with SIRS after PCNL. In total, 1259 patients underwent PCNL and were enrolled in the study. The study utilized both propensity score matching (PSM) analysis and regression analysis to identify risk factors for post-PCNL SIRS. The incidence of SIRS after PCNL was 9.6 % in the study and patients with postoperative SIRS had longer hospital stays and higher hospital costs. After minimizing the potential influence of confounding factors through the use of PSM, we found a significant association between the preoperative use of glucocorticoids and the occurrence of SIRS in patients undergoing PCNL. Based on our analysis, we can conclude that the preoperative administration of glucocorticoids represents an independent risk factor for the development of SIRS in these patients.
Sujet(s)
Néphrolithotomie percutanée , Humains , Femelle , Néphrolithotomie percutanée/effets indésirables , Glucocorticoïdes/effets indésirables , Études rétrospectives , Syndrome de réponse inflammatoire généralisée/épidémiologie , Syndrome de réponse inflammatoire généralisée/étiologie , Facteurs de risqueRÉSUMÉ
BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for an important mortality rate worldwide. We aimed to evaluate the actual imputability of SARS-CoV-2 on the mortality rate associated with SARS-CoV-2-related illnesses in the pediatric intensive care unit (PICU). Secondary objectives were to identify risk factors for death. METHODS: This national multicenter comparative study comprised all patients under 18 years old with positive SARS-CoV-2 polymerase chain reactions (PCRs) [acute corona virus disease 2019 (COVID-19) or incidental SARS-CoV-2 infection] and/or pediatric inflammatory multisystem syndrome (PIMS) recorded in the French PICU registry (PICURe) between September 1, 2021, and August 31, 2022. Included patients were classified and compared according to their living status at the end of their PICU stay. Deceased patients were evaluated by four experts in the field of pediatric infectiology and/or pediatric intensive care. The imputability of SARS-CoV-2 as the cause of death was classified into four categories: certain, very probable, possible, or unlikely, and was defined by any of the first three categories. RESULTS: There were 948 patients included of which 43 died (4.5%). From this, 26 deaths (67%) could be attributed to SARS-CoV-2 infection, with an overall mortality rate of 2.8%. The imputability of death to SARS-CoV-2 was considered certain in only one case (0.1%). Deceased patients suffered more often from comorbidities, especially heart disease, neurological disorders, hematological disease, cancer, and obesity. None of the deceased patients were admitted for pediatric inflammatory multisystem syndrome (PIMS). Mortality risk factors were male gender, cardiac comorbidities, cancer, and acute respiratory distress syndrome. CONCLUSIONS: SARS-CoV-2 mortality in the French pediatric population was low. Even though the imputability of SARS-CoV-2 on mortality was considered in almost two-thirds of cases, this imputability was considered certain in only one case.